**PATENT** 

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Glucksmann, Maria A.

**Application No.:** 

10/085,233

Group No.:

1645

Filed: For:

February 28, 2002

Examiner:

N/A

93870, A HUMAN G-PROTEIN COUPLED RECEPTOR AND USES THEREFOR

**Assistant Commissioner for Patents** Washington, D.C. 20231

#### INFORMATION DISCLOSURE STATEMENT

# List of Sections Forming Part of This Information Disclosure Statement

The following sections are being submitted for this Information Disclosure Statement:

- 1. [x]**Preliminary Statements**
- 2. Forms PTO/SB/08A and 08B (substitute for Form PTO-1449) {X}
- 3. Copies of Listed Information Items Accompanying This Statement [X]
- 4. [X] Translation(s) of Non-English Language Documents

### CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\*

I hereby certify that, on the date shown below, this correspondence is being:

### **MAILING**

× deposited with the United States Postal Service in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10\*

× with sufficient postage as first class mail.

Date July 3, 2002

as "Express Mail Post Office to Address"

Mailing Label No.

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office.

∕Simonne Corriveau

(type or print name of person certifying)

\*WARNING:Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing, 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

### **Preliminary statements**

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. section 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

## Copies of Listed Information Items Accompanying This Statement

Legible copies of all items listed in Forms PTO/SB/08A and 08B (substitute for Form PTO-1449) accompany this information statement.

### Translation(s) of Non-English Language Documents

- [ ] Submitted herewith is an English translation of the following foreign language patents, publications or information or of those portions of those patents, publications or information considered to be material:
- (x) No English language translations of the foreign language patents, publications or information or parts thereof are readily available, except for those listed above.
- [] The following foreign language documents submitted are believed to be the equivalent or substantial equivalent of the English language documents identified below, which are also submitted herewith.

July 3, 2002

MILLENNIUM PHARMACEUTICALS, INC.

Jean M. Silveri

Registration No. 39,030

75 Sidney Street

Cambridge, MA 02139

Telephone - 617-679-7336

Facsimile - 617-551-8820

PTO/SB/08A (
--------------

Approved for use through 10/31/99. OMB 0654-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons guired to respond ( ) a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PT INFORMATION STATEMENT BY

> (use as many sheets as necessary) of

1

Please type a plus sign (+) inside this box

Sheet

Complete if Known					
Applicati n Numb r	10/085,233				
Filing Date	February 28, 2002				
First Named Inv nt r	Glucksmann, Maria A.				
Group Art Unit	1645				
Examiner Name	N/A				
Attorney Docket Number	MPI01-021P1RNM				

				U.S. PATENT DOCUME	NTS			
		U.S. Pate	nt Document		Date of Publication of	Pages, Columns, Lines, Where		
Examiner Initials*	Cite No. <sup>1</sup>	Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Cited Document (MM-DD-YYYY)	Relevant Passages or Relevan Figures Appear		
				·				
				<del></del>		<u> </u>		
		ļ <u>.</u>				و د ا		
						<u> </u>		
				<del></del>				
		<u> </u>				<u> </u>		
						⇒ 61 -		
						600		
						29		
		<u> </u>						

				FORE	IGN PATENT DOCU	JMENTS		
Examiner Initials*	Cite No.1	Fo Office <sup>3</sup>	reign Patent Do	cument Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document (MM-DD-YYYY)	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	ВА	wo	02/26825		Incyte Genomics	04-04-2002	6-8, 10-11, 17, 28, 30, 71, 95, 97, 111 and 27 of sequence listing	
	BB	wo	01/36473		Pharmacia & Upjohn Company	05-25-2001	14-15, 64, 79, 89, 113, 118 and 15, 54 of sequence listing	
	BC	wo	01/96567		Takeda Chem Ind Ltd.	12-20-2001	87 (claim 5)	
	BD	wo	01/57182		Human Genome Sciences, Inc.	08-09-2001	105, 1749	

Examiner	Date	
Signature	Considered	

<sup>&</sup>lt;sup>1</sup>Unique citation design number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japan se patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of docum int by th appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>8</sup>Applicant is to place a check mark h re if English languag Translation is attached.



Burden Hour Statement: This form is stimat d to tak 2.0 hours to complet . Time will vary d pending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a	plus sign (+)	inside this box	<del>&gt;</del> ∣	+
---------------	---------------	-----------------	-------------------	---

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031 Patent and Trad mark Office: U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1985, no persons a sequired to respond to a collection of information unless it contains a valid OMB control number.

	r form 1449B/PT0			Com	plete if Known
INFOR	ΚΛΩΤΙΩΝ	ટાલ્ફી	CLOSTIRE	Application Number	10/085,233
MADELLA ONLY				Filing Date	February 28, 2002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			#PEICAN I	First Named Inventor	Glucksmann, Maria A.
				Group Art Unit	1645
(use as many sheets as necessary)			necessary)	Examiner Name	N/A
Sheet	1	of	1	Attorney Docket Number	MPI01-021P1RNM

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Include the name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the iten (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publishe (nitials* No.1			
	CA	Kaul, R.K., et al., "Homo sapiens chromosome 7 clone RP11-605P22, complete sequence", January 26, 2001, (sequence) GenBank [online]. Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on June 26, 2002]. Retrieved from the Internet: <url: <a="" href="http://www.ncbi.nlm.nih.gov/">http://www.ncbi.nlm.nih.gov/. GenBank Accession No. AC083865.</url:>	
		JEC	
		TECH CENTER 1600/2900	JUL 1 5
		1600/2900	2002
Examiner	<del></del>	Date Considered	

Examiner	Date	<u> </u>
Signature	Considered	<u> </u>

Burden Hour Statement: This form is stimated to tak 2.0 hours to complete. Time will vary depending upon the ne ds of the individual cas . Any comments on the amount of time you are required to compl te this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.



<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with n xt communication to applicant.

<sup>&</sup>lt;sup>1</sup>Unique citation design number. <sup>2</sup>Applicant is to place a check mark here is English languag Translation is attached.